Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

[1]  V. Pavone,et al.  Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi , 2013 .

[2]  K. Schwarz,et al.  High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. , 2013, Blood.

[3]  J. Ritz,et al.  Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. , 2013, Blood.

[4]  R. Gascoyne,et al.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Deeg,et al.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. V. Hoef.  Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten , 2013 .

[7]  Y. Min,et al.  Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Rosenwald,et al.  Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). , 2012, The Lancet. Oncology.

[9]  L. Staudt,et al.  The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study , 2012 .

[10]  J. Vose,et al.  Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? , 2012, Blood.

[11]  A. Nademanee,et al.  Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. , 2012, Blood.

[12]  B. Narasimhan,et al.  Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. , 2012, Blood.

[13]  T. Molina,et al.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.

[14]  H. Einsele,et al.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.

[15]  S. Mackinnon,et al.  Allogeneic transplantation for lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Nagler,et al.  Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Molina,et al.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.

[19]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[21]  Brit B. Turnbull,et al.  TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. , 2009, Blood.

[22]  R. Gale,et al.  Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation , 2009, British journal of haematology.

[23]  S. Mackinnon,et al.  Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Behre,et al.  Rituximab reduces the incidence of acute graft-versus-host disease. , 2006, Blood.

[25]  M. Sorror,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Fanin,et al.  Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome , 2007, Leukemia.

[27]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[28]  C. Craddock,et al.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation , 2005, The Lancet.

[29]  N. Schmitz,et al.  Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect , 2004, Bone Marrow Transplantation.

[30]  A. Zelenetz,et al.  Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. , 2003, Blood.

[31]  N. Schmitz,et al.  An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation , 2003, Bone Marrow Transplantation.

[32]  N. Schmitz,et al.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. , 2002, Blood.

[33]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[34]  A. Marmont.  Stem Cell Transplantation , 1999, Bone Marrow Transplantation.

[35]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Blay,et al.  The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. , 1998, Blood.

[37]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[38]  J. Szer,et al.  The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation , 1991, British journal of haematology.

[39]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[40]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen , 1987 .

[41]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. , 1987, Blood.

[42]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[43]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.